Why should you invest in this smallcase?

Overall Pharma sector was under pressure in the past 2 years. However, we believe progressive improvement in business outlook, primarily driven by healthy growth in domestic business, normalization of price erosion in US business coupled with big ticket launches for selected companies, and favorable currency movement.

Know how this smallcase was created


Download key points about this smallcase

Created by Axis Securities Ltd (ASL) Research

Past Performance vs 

Equity Large Cap

Value of ₹ 100 invested once on
inception of this smallcase

Feb 26, 2015

would be
Pharma - Multi Cap
₹ 217.35
Equity Large Cap
₹ 134.24


Past performance doesn't guarantee future returns & is inclusive of all rebalances. Download chart